Summary
Classifies gastrointestinal lesion software devices, including AI-enabled systems that analyze endoscopic images to identify suspected lesions, as class II devices subject to special controls.
Healthcare Implications
Establishes the FDA regulatory pathway and special-control expectations for AI-assisted gastrointestinal lesion detection software.